BRANDES

Brandes European Value Fund

A sub-fund of Brandes Investment Funds Plc

FUND OBJECTIVE

Long-term capital appreciation by investing primarily in equity and equity related securities of issuers carrying out their activities predominantly in Europe.


FUND INFORMATION

Total Net	C400.0
Asset Value (mil.)	€420.8
(1111.)	

Legal Structure UCITS

Manager	Brandes Investment Partners (Europe) Limited
Trade Frequency	Daily
Dealing Cutoff	16:00 New York Time
Registered	AT, CH, DE, ES, FR, IE, LUX, NL, UK
Management Fee	0.70%
SFDR Classification	Article 8

MORNINGSTAR STYLE BOX™



The Morningstar Style Box[™] reveals a fund's investment strategy by showing its investment style and market capitalization based on the fund's portfolio holdings.



The Brandes European Value Fund (the "Fund") Class I EUR rose 7.02%, underperforming its index, the MSCI Europe Index, which increased 7.63% in the quarter, and outperforming the MSCI Europe Value Index, which appreciated 4.87%.

Positive Contributors

The Fund's performance was meaningfully bolstered by holdings in the industrials and financials sectors, with notable contributions from several companies. Aerospace and defence company Rolls-Royce emerged as a standout, alongside banking institutions Intesa Sanpaolo in Italy, Nova Ljubljanska Banka (NLB) in Slovenia, and Addiko Bank in Austria.

Rolls-Royce continued to benefit from the ongoing recovery in passenger air travel that has led to solid revenue growth, expanding profit margins, healthier cash-flow generation, and an improved balance sheet. These positive fundamental developments helped confirm our long-term thesis around franchise quality, balance sheet durability and end-market recovery potential. Moreover, record backlogs highlighted the appealing long-term secular growth outlook for global passenger air travel in an industry that has historically allowed incumbents to generate attractive returns on capital. Consequently, we revised our intrinsic value estimate upward and believe Rolls-Royce continues to offer an attractive risk/reward trade-off at current valuation levels.

NLB experienced the ongoing benefits of a consolidated and improved end-market, coupled with a favourable interest rate environment, while Addiko Bank enjoyed a material rise in its share price following a tender offer from shareholder Agri Europe.

Additionally, German software firm SAP saw a notable increase in its share price as it progressed on its customer migration to the cloud. Market optimism about its future growth prospects and potential margin improvement has further fuelled market sentiment in favour of the company.

Performance Detractors

Notable detractors included several health care-related investments, such as France-based Euroapi, Spain-based Grifols, Netherlands-based Koninklijke Philips and Germany-based Fresenius SE.

Euroapi, a pharmaceutical ingredient manufacturer, encountered a share-price drop due to weaker-than-expected earnings results and a temporary production suspension at a manufacturing facility in Italy. Despite these near-term challenges, we view Euroapi as a potential longer-term recovery story, particularly because it only recently began operating as an independent entity following its spinoff from Sanofi. It offers margin and profitability improvement potential over time as its pharmaceutical end-markets grow. However, given short-term risks associated with the difficult biotech funding environment and Euroapi's initial high post-spinoff fixed-cost structure, we have maintained a conservative allocation.

Biotechnology firm Grifols grappled with multiple declines in its share price following a short seller's report that questioned the company's debt and corporate governance practices. In our opinion, the risks highlighted in the report had been largely known, and we maintained our position in the company despite the volatility—albeit now at a lower weighting due to the share-price decline. While we have long been concerned with the company's balance sheet, there is a potential near-term catalyst for its improvement as



Grifols is expected to complete the sale of its ownership stake in Shanghai RAAS in the first half of this year and use the proceeds to pay down a significant portion of its debt.

We continue to believe there is potentially meaningful upside in the stock. Grifols' plasma business weathered considerable challenges amid the COVID-19 pandemic, including decreased blood donations and higher costs associated with compensating donors. The company had also made substantial investments to expand capacity for future growth, which further weighed on its profitability. While the recovery has been slower than anticipated, we believe that the expected completion of the Shanghai RAAS transaction is a key positive and that Grifols is attractively valued, trading at a single-digit multiple of pre-COVID earnings. Additionally, we appreciate Grifols' competitive position in a consolidated industry with appealing potential growth.

Other detractors included Luxury goods companies Swatch and Kering. Kering fell after announcing an expected revenue drop during the first half of 2024 because the new creative director of its Gucci brand launched a collection in the first quarter and results won't be realised until the second half of the year.

Select Activity in the Quarter

We divested our longtime holding in Netherlands-based insurer Aegon, as well as Ireland-based health care company Avadel Pharmaceuticals when they reached our estimates of their intrinsic value.

Avadel is a biotechnology company with a portfolio of hospital and generic products. We first bought its stock in 2017 when it traded at an attractive valuation because the market wasn't ascribing much, if any, value to its drug development pipeline. Since initiating our first position, our experience has been eventful and included two substantial drawdowns. But with its recent appreciation, Avadel has been a strong contributor over our full ownership cycle.

Initially, the company's value came primarily from three main products, which had deployed Avadel's strategy of submitting unapproved marketed drugs (UMDs) to the FDA and filing the required documentation to gain approval. Clinical trials aren't needed for UMDs launched before 1962, so getting FDA approval can secure exclusivity until other generic manufacturers respond. Avadel's focus was on specialty branded and generic drugs, but it also developed its own drugs and used its proprietary drug delivery platform for distribution. Additionally, the company had a significantly net cash balance sheet comprising nearly half of its market cap and was repurchasing shares. However, it had recently acquired a new narcolepsy drug and was working on commercialising it. Given the product concentration risk and range of intrinsic value, we kept our allocation on the smaller side.

During our ownership period, the stock initially struggled due to increased competition against its narcolepsy drug and heightened investment to fund Phase 3 research on a medication in development. Subsequently, Avadel abandoned plans to market its initial narcolepsy drug and focused on the new drug in its pipeline. While the company generated cash flow from other pharmaceuticals, its emphasis on research and development increased its investment risk and therefore called for a smaller allocation. The stock eventually rebounded as market sentiment regarding the potential of its Phase 3 drug improved. However, it faced another falloff when a patent issue vis-avis a competitor delayed launch and raised financing concerns. Nevertheless, over the past year, as Avadel began commercialising its latest narcolepsy treatment, its shares experienced noteworthy appreciation, eventually reaching our estimate of the company's intrinsic value. So, we sold our position.

We decided to divest our longstanding holding in Aegon. Aegon primarily operates in the life insurance sector, with a presence in the U.S., Europe, and Asia. The United States contributes the majority of its earnings. During the past few years, Aegon has pursued a turnaround effort by bolstering its capital position, restructuring its business, and divesting non-core assets. This strategic shift aims to shift Aegon from a primarily spread-based, capital-intensive business model to one that emphasises fee-based operations.

During this turnaround, Aegon's shares demonstrated solid performance, reflecting the success of its restructuring initiatives. A notable milestone was the recent sale of its Dutch business to a competitor, which aimed at streamlining operations and optimising its portfolio. Proceeds from this divestment were used to return excess capital to shareholders.

As Aegon's shares appreciated and aligned with our estimate of intrinsic value, we concluded that it no longer offered an attractive risk/reward trade-off. We therefore decided to divest.

Current Positioning

The Fund holds key overweight positions in communication services and consumer staples, while maintaining significantly lower allocations to technology and industrials than the index.

On a geographic basis, the Fund's largest allocations continue to be in France and the United Kingdom. The Fund remains underweight in Germany and Switzerland, as well as to companies in the Nordic Region. Within the index, there has been notable divergence in sector performance. Technology-focused companies—both in the technology and industrials sectors—notably outperformed the MSCI Europe Index, as did holdings in the consumer discretionary and financials sectors. Meanwhile, more defensive sectors, such as consumer staples and utilities, materially underperformed.

While MSCI Europe Value underperformed the MSCI Europe Index during the first quarter, value stocks continued to trade in the least-expensive decile relative to growth (MSCI Europe Growth) since the inception of the style indices. This was evident across various valuation measures, including price/earnings, price/cash flow, and enterprise value/sales. Historically, such discount levels have often signalled attractive subsequent returns for value stocks.

The Fund, guided by our value philosophy and process, has tended to outperform the MSCI Europe Value Index when it has outperformed the MSCI Europe Index. We believe the Fund is an excellent complement and diversifier to passive and growth-oriented strategies.

We remain optimistic about the long-term prospects of the companies owned by the Fund. As of 31 March 2024, the Fund traded at what we consider more compelling valuation levels than the MSCI Europe Index and the MSCI Europe Value Index.


Performance (%)¹

									Since Ir	ception	
	NAV	1 mo	3 mo	YTD	1 yr	3 yr	5 yr	10 yr	Fund	Index	Inception Date
Class I EUR	€ 59.77	6.14	7.02	7.02	22.25	11.41	10.32	6.95	8.85	7.82	26/2/2003
Class I1 EUR	€ 15.45	6.11	7.01	7.01	22.27	11.37	10.56		8.06	8.88	14/6/2016
Class B EUR	€ 12.78	6.06	6.86	6.86	21.25				8.98	8.11	24/5/2021
Class A EUR	€ 39.35	6.09	6.81	6.81	21.26	10.52	9.65	6.24	6.84	7.15	17/7/2003
Class A1 EUR	€ 14.29	6.09	6.81	6.81	21.29	10.61	10.35		6.14	7.01	5/10/2015
Class R EUR	€ 13.22	6.10	7.04	7.04	22.18				10.14	8.06	10/5/2021
MSCI Europe Index EUR		3.94	7.63	7.63	14.79	9.22	8.79				
Class I USD	\$ 46.72	5.97	4.61	4.61	21.63	8.39	9.47	4.38	7.54	7.06	14/1/2003
Class A USD	\$ 40.93	5.87	4.36	4.36	20.60	7.43	8.68	3.64	7.55	7.68	12/2/2003
Class A1 USD	\$ 11.29	5.81	4.31	4.31	20.58				5.67	3.73	7/7/2021
MSCI Europe Index USD		3.74	5.23	5.23	14.11	6.18	7.95				
Class I GBP	£45.65	5.97	5.65	5.65	18.88	11.43	9.86	7.11	7.80	7.76	13/1/2004
Class I1 GBP	£15.88	6.01	5.63	5.63	18.86	11.64	10.08		8.33	9.48	10/6/2016
Class A GBP	£31.71	5.88	5.35	5.35	17.71	10.52	9.03	6.60	6.43	6.96	27/9/2005
MSCI Europe Index GBP		3.88	6.19	6.19	11.69	9.35	8.62				

Calendar Year Returns (%)1


	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Class I EUR	4.58	18.94	7.62	-0.79	-10.40	17.83	-5.03	23.16	-4.47	25.65
MSCI Europe Index EUR	6.84	8.22	2.58	10.24	-10.57	26.05	-3.32	25.13	-9.49	15.83

Growth of €10,000 Since Inception¹



Past performance may not be a reliable guide to future performance. Periods of greater than one year have been annualized. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units. Changes in exchange rates may have an adverse effect on the value price or income of the product. It is not possible to invest directly in an index.

Relative Quarterly Impact (%)²



¹Source: Brandes, MSCI. Allocations and performance data as of 31/3/2024. Holdings are subject to change at any time and should not be considered a recommendation to buy or sell particular securities. Current and future fund holdings are subject to risk. Past performance is not a guarantee of future results. Changes in exchange rates may have an adverse effect on the value price or income of the product. ²Source: FactSet. FactSet data is holdings-based. Price, weights, foreign exchange rates, and returns shown may differ slightly from those of the Fund.

> FOR PROFESSIONAL INVESTORS ONLY PAGE 4

BRANDES


Top 10 Holdings¹

Company	%
Rolls-Royce Holdings PLC	3.57
Heineken Holding NV	2.79
UBS Group AG	2.66
SAP SE	2.62
Sanofi SA	2.56
Intesa Sanpaolo SpA	2.47
WPP Plc	2.40
Henkel AG & Co KGaA	2.25
GSK PLC	2.20
Nova Ljubljanska Banka dd	2.14

Characteristics1

	Fund
Price/Book	1.1x
Price/Earnings	11.4x
Price/Cash Flow	6.1x
Equity Yield (%)	3.3
Active Share (%)	86.3
Number of Holdings	65
Avg. Market Cap (billions)	€40.3
Security Turnover (TTM, %)	30.2
Cash (%)	1.2

Capitalization Summary (%)¹



Best Performing Stocks²

Top 5 – Last Quarter

Security	Allocation (%)	Return (%)	Impact (%)	Country	Industry
Rolls-Royce Holdings plc	3.6	44.3	1.3	GB	Aerospace & Defense
SAP SE	2.6	29.4	0.7	DE	Software
Intesa Sanpaolo S.p.A.	2.5	27.2	0.6	IT	Banks
GSK plc	2.2	20.5	0.5	GB	Pharmaceuticals
Nova Ljubljanska banka d.d. Sponsored GDR RegS	2.1	28.0	0.5	SI	Banks

Worst Performing Stocks²

	Bottom	5	-	Last	Quarter
--	--------	---	---	------	---------

Security	Allocation (%)	Return (%)	Impact (%)	Country	Industry
Grifols, S.A. Pref Class B	1.5	-42.8	-1.1	ES	Biotechnology
Euroapi SA	0.4	-51.2	-0.4	FR	Pharmaceuticals
Koninklijke Philips N.V.	1.8	-11.8	-0.3	NL	Health Care Equipment & Supplies
Swatch Group Ltd. Registered	2.0	-11.4	-0.3	CH	Textiles Apparel & Luxury Goods
Fresenius SE & Co. KGaA	1.7	-10.9	-0.2	DE	Health Care Providers & Services

Portfolio Changes Trailing Twelve Months¹

Period	Complete Sales - Country - Industry	Period	New Buys - Country - Industry	
01 2024	Aegon Ltd = NL = Insurance	Q1 2024	No New Buys	
~ ·····	Avadel Pharmaceuticals PLC = IE = Pharmaceuticals		LISI SA = FR = Aerospace & Defense	
	Buzzi SpA • IT • Construction Materials	Q4 2023	Montana Aerospace AG = CH = Aerospace & Defense	
Q4 2023	Sandoz Group AG = CH = Pharmaceuticals		Valiant Holding AG = CH = Banks	
	Swiss Re AG • CH • Insurance	02 2022	Cie Financiere Richemont SA = CH = Textiles, Apparel & Luxury Goods	
03 2023	Imperial Brands PLC = GB = Tobacco	Q3 2023	Heineken Holding NV = NL = Beverages	
QJ 2025	Mitie Group PLC = GB = Commercial Services & Supplies		Euroapi SA • FR • Pharmaceuticals	
02 2023	De La Rue PLC = GB = Commercial Services & Supplies Q2		Kering SA = FR = Textiles, Apparel & Luxury Goods	
QZ 2023	Haleon PLC - GB - Personal Care Products		Willis Towers Watson PLC • IE • Insurance	

¹Source: Brandes, FactSet, MSCI. Allocations and performance data as of 31/3/2024. Holdings are subject to change at any time and should not be considered a recommendation to buy or sell particular securities. Current and future fund holdings are subject to risk. Past performance is not a guarantee of future results. Changes in exchange rates may have an adverse effect on the value price or income of the product. ²Source: FactSet. FactSet data is holdings-based. Price, weights, foreign exchange rates, and returns shown may differ slightly from those of the Fund.

Country Allocation (%)¹

Country	Fund	Index
United Kingdom	25.0	22.3
France	21.0	18.6
Switzerland	11.2	14.4
Germany	9.2	13.4
Spain	7.4	4.1
Ireland	5.6	0.5
Netherlands	4.6	7.8
Italy	4.2	4.3
Austria	2.9	0.3
Belgium	2.4	1.4
Slovenia	2.1	
Hungary	1.7	
Luxembourg	1.5	
Other	0.0	12.9

13 Total number of countries in the fund 5 Total number of MSCI Europe Index countries not in the fund

No exposure to countries that represent 12.9% of the index

Country Changes Trailing Twelve Months (%)¹

5		()
Mar-23	Mar-24	Change
2.4	4.6	2.2
9.8	11.2	1.4
20.3	21.0	0.7
1.1	1.7	0.6
	2.4 9.8 20.3	2.44.69.811.220.321.0

Largest Decreases	Mar-23	Mar-24	Change
Italy	7.1	4.2	-2.9
United Kingdom	27.0	25.0	-2.0
Germany	11.1	9.2	-1.9
Belgium	2.7	2.4	-0.3

Regional Changes Trailing Twelve Months (%)¹

	Mar-23	Mar-24	Change
Developed Markets	96.8	95.0	-1.8
Emerging Markets	2.8	3.8	1.0

Country Return Impact (%)²

			Alloc	ation	Return Return Imp		Return Impact		
			Fund	Index	Fund	Index	Fund	Index	Rel. Impact
		United Kingdom	24.9	21.8	11.1	5.2	2.7	1.1	1.6
		Ireland	5.5	1.1	20.7	19.5	1.2	0.2	1.0
-	Top 5	Germany	9.2	13.4	9.5	9.5	0.9	1.2	-0.3
tei		France	20.9	17.3	3.0	8.0	0.6	1.4	-0.8
Quarter		Austria	2.9	0.3	19.9	2.8	0.5	0.0	0.5
ğ		Netherlands	4.6	9.1	-5.2	17.4	-0.3	1.5	-1.8
ast		Spain	7.3	4.1	-2.3	10.6	-0.2	0.4	-0.6
La	Bottom 5	Belgium	2.4	1.4	-0.8	4.1	0.0	0.1	-0.1
	Dottom o	Luxembourg	1.5	0.0	15.0	0.0	0.2	0.0	0.2
		Switzerland	11.1	14.4	2.3	1.0	0.3	0.1	0.1
hs		United Kingdom	24.9	21.4	29.5	10.6	7.1	2.3	4.8
Months	Top 5	Germany	9.2	13.4	26.2	15.5	2.6	2.0	0.6
ž	1005	Switzerland	11.1	14.4	23.8	7.7	2.3	1.2	1.1
		Ireland	5.5	1.4	37.8	30.5	2.2	0.4	1.8
el		Italy	4.2	4.3	34.8	39.0	1.8	1.4	0.4
Twelve		Belgium	2.4	1.4	1.4	2.0	0.0	0.0	0.0
-		Luxembourg	1.5	0.0	7.5	0.0	0.1	0.0	0.1
	Bottom 5	Netherlands	4.6	9.1	24.5	24.2	0.9	2.1	-1.2
Trailing		Austria	2.9	0.3	38.4	15.5	1.0	0.0	1.0
Ē		Slovenia	2.1	0.0	67.3	0.0	1.1	0.0	1.1

¹Source: Brandes, MSCI. Allocations and performance data as of 31/3/2024. Holdings are subject to change at any time and should not be considered a recommendation to buy or sell particular securities. Current and future fund holdings are subject to risk. Past performance is not a guarantee of future results. Changes in exchange rates may have an adverse effect on the value price or income of the product. The referenced index is the MSCI Europe Index. ²Source: FactSet. FactSet data is holdings-based. Price, weights, foreign exchange rates, and returns shown may differ slightly from those of the Fund.

Top 15 Industry Allocation (%)¹

_		. ,	
	Industry	Fund	Index
	Banks	15.2	8.5
	Media	6.6	0.5
	Pharmaceuticals	6.5	11.9
	Aerospace & Defense	6.5	3.4
	Consumer Staples Distr. & Retail	6.4	0.8
	Beverages	5.8	2.3
	Textiles, Apparel & Luxury Goods	5.5	4.8
	Health Care Equip. & Supplies	4.8	2.0
	Oil, Gas & Consumable Fuels	4.3	5.3
	Diversified Telecom Services	4.0	1.8
	Food Products	2.9	3.7
	Capital Markets	2.7	3.1
	Software	2.6	2.4
	Insurance	2.5	5.4
	Personal Care Products	2.4	2.6

Top 15 Index Industries not in the Fund (%)¹

	(-)
Industry	Index
Semiconductors & Equipment	4.6
Chemicals	3.4
Electrical Equipment	2.5
Electric Utilities	2.0
Professional Services	1.9
Metals & Mining	1.9
Hotels, Restaurants & Leisure	1.8
Industrial Conglomerates	1.5
Financial Services	1.4
Building Products	1.0
Life Sciences Tools & Services	0.8
Tobacco	0.7
Air Freight & Logistics	0.6
Broadline Retail	0.5
Paper & Forest Products	0.4

28

Total number of industries in the fund

37

Total number of MSCI Europe Index industries not in the fund

No exposure to industries that 29.2% of the index

Industry Changes Trailing Twelve Months (%)¹

Largest Increases	Mar-23	Mar-24	Change
Aerospace & Defense	2.6	6.5	3.9
Textiles, Apparel & Luxury Goods	2.3	5.5	3.2
Beverages	3.4	5.8	2.4
Banks	13.2	15.2	2.0


Largest Decreases	Mar-23	Mar-24	Change
Construction Materials	6.7	1.3	-5.4
Pharmaceuticals	8.5	6.5	-2.0
Commercial Services & Supplies	2.7	1.2	-1.5
Tobacco	1.2		-1.2

Industry Return Impact (%)²

		Alloc	cation	Re	turn		Return Impact	
	_	Fund	Index	Fund	Index	Fund	Index	Rel. Impact
	Banks	15.2	8.5	20.9	13.7	2.8	1.1	1.8
	Aerospace & Defense	6.4	3.4	22.3	30.6	1.2	0.9	0.3
Top 5	Media	6.5	0.5	14.0	11.2	0.9	0.1	0.8
Quarter	Software	2.6	2.4	29.4	21.0	0.7	0.5	0.2
n)	Insurance	2.5	5.4	11.4	10.9	0.4	0.6	-0.1
2	Biotechnology	1.5	0.5	-42.8	-3.3	-1.1	0.0	-1.1
Bottom 5	Health Care Equipment & Supplies	4.8	2.0	-6.8	6.6	-0.4	0.1	-0.5
Bottom 5	Health Care Providers & Services	1.7	0.2	-10.9	-6.2	-0.2	0.0	-0.2
	Consumer Staples Distribution & Retail	6.4	0.8	-2.9	-2.6	-0.2	0.0	-0.2
	Textiles, Apparel & Luxury Goods	5.5	4.8	-3.2	12.6	-0.1	0.6	-0.7
<u>v</u>								
Top 5	Banks	15.2	8.5	41.5	35.4	5.3	2.6	2.7
Top 5	Aerospace & Defense	6.4	3.4	160.6	54.5	4.1	1.4	2.7
<u>د</u>	Construction Materials	1.3	1.1	52.3	61.2	1.6	0.5	1.1
	Software	2.6	2.4	55.5	49.0	1.2	0.9	0.3
I welve	Oil, Gas & Consumable Fuels	4.3	5.3	21.9	14.5	1.2	0.8	0.4
-	Textiles, Apparel & Luxury Goods	5.5	4.8	-25.3	0.2	-1.0	-0.1	-1.0
Bottom 5	Торассо	0.0	0.7	-8.6	-2.2	-0.1	0.0	-0.1
all	Household Products	2.2	0.7	1.7	-14.9	0.1	-0.1	0.2
=	Biotechnology	1.5	0.5	-8.1	-5.6	0.1	0.0	0.1
	Wireless Telecommunication Services	1.5	0.2	7.4	-10.5	0.1	0.0	0.1

¹Source: Brandes, MSCI. Allocations and performance data as of 31/3/2024. Holdings are subject to change at any time and should not be considered a recommendation to buy or sell particular securities. Current and future fund holdings are subject to risk. Past performance is not a guarantee of future results. Changes in exchange rates may have an adverse effect on the value price or income of the product. The referenced index is the MSCI Europe Index. ²Source: FactSet. FactSet data is holdings-based. Price, weights, foreign exchange rates, and returns shown may differ slightly from those of the Fund.

Sector Allocation (%)1



Sector Changes Trailing Twelve Months (%)¹

Largest Increases	Mar-23	Mar-24	Change
Consumer Discretionary	5.2	8.7	3.5
Industrials	9.1	12.0	2.9
Financials	19.1	20.4	1.3
Real Estate	1.6	1.8	0.2

Largest Decreases	Mar-23	Mar-24	Change
Materials	6.7	1.3	-5.4
Energy	5.4	4.3	-1.1
Health Care	15.6	14.5	-1.1
Utilities	2.0	1.3	-0.7

Sector Return Impact (%)²

		Alloo	cation	Re	turn	Return Impact		
		Fund	Index	Fund	Index	Fund	Index	Rel. Impact
	Financials	20.4	18.4	17.1	11.0	3.3	1.9	1.4
	Industrials	11.9	16.4	17.1	9.7	1.8	1.6	0.3
_	Communication Services	12.1	3.0	12.7	4.4	1.5	0.1	1.4
Quarter	Information Technology	2.6	8.1	29.4	17.8	0.7	1.4	-0.7
na	Consumer Staples	19.7	10.7	2.1	-1.0	0.4	-0.1	0.5
	Consumer Discretionary	8.7	11.1	2.8	12.1	0.3	1.3	-1.0
Last	Materials	1.3	7.0	20.1	3.8	0.3	0.2	0.1
	Real Estate	1.8	0.8	17.4	-0.9	0.3	0.0	0.3
	Energy	4.3	5.4	2.3	4.0	0.1	0.2	-0.1
	Utilities	1.3	3.8	-2.6	-4.9	0.0	-0.2	0.2
	Health Care	14.4	15.4	-8.4	8.0	-1.5	1.3	-2.8
<i>(</i>)	Financials	20.4	18.4	39.0	28.9	7.3	4.8	2.5
Months	Industrials	11.9	16.4	75.6	23.4	6.0	3.6	2.4
5	Consumer Staples	19.7	10.7	10.3	-5.5	2.2	-0.8	3.0
Σ	Communication Services	12.1	3.0	16.6	4.2	1.9	0.1	1.8
N N	Materials	1.3	7.0	52.3	12.7	1.6	0.9	0.7
Iwelve	Information Technology	2.6	8.1	55.5	31.0	1.2	2.3	-1.1
=	Energy	4.3	5.4	21.9	14.9	1.2	0.8	0.4
6u	Health Care	14.4	15.4	4.6	12.1	0.9	1.8	-0.9
	Real Estate	1.8	0.8	46.6	30.3	0.8	0.2	0.5
Irailing	Utilities	1.3	3.8	16.8	-0.2	0.4	0.0	0.4
_	Consumer Discretionary	8.7	11.1	-10.8	9.0	-0.6	1.0	-1.5

¹Source: Brandes, MSCI. Allocations and performance data as of 31/3/2024. Holdings are subject to change at any time and should not be considered a recommendation to buy or sell particular securities. Current and future fund holdings are subject to risk. Past performance is not a guarantee of future results. Changes in exchange rates may have an adverse effect on the value price or income of the product. The referenced index is the MSCI Europe Index. ²Source: FactSet. FactSet data is holdings-based. Price, weights, foreign exchange rates, and returns shown may differ slightly from those of the Fund.

Brandes at a Glance

Share Class Details

Brandes Investment Partners (Europe) Limited Manager
Graham & Dodd, bottom-up value
Investment Style
Dublin, Ireland
Office location
Brandes Investment Partners L.P., San Diego, CA, USA
Headquarters
1974
Year Founded
\$26.0 Billion
Total Assets
194 / 34
Employees / Investment Professionals
100%
Employee Owned

Fund Service Providers

	State Street Fund Services (Ireland) Limited Administrator
	State Street Custodial Services (Ireland) Limited Depositary
	State Street Fund Services (Ireland) Limited
-	KPMG Auditor

Total Expense Morningstar Rating^{*} Share Class ISIN CUSIP WKN Sedol Bloomberg Valoren Inception Date Ratio %1 Overall² Class I USD IE0031574860 G1309T162 3157486 BRANEEI 1555180 260193 14/1/2003 0.85 **** Class I EUR IE0031574977 G1309T246 3157497 BRANEUI 1555573 260196 26/2/2003 0.88 **** Class I GBP IE0031575057 G1309T261 3157505 BRANGBP 1555581 260199 13/1/2004 0.86 **** Class I1 USD IE00BYWTYT98 G1309T709 **BYWTYT9** BRNEI1U 37873322 A2DU24 Class I1 EUR 29416456 IE00BYXWTT24 G1309T568 BYXWTT2 BRAEI1E A14Y7Q 14/6/2016 0.86 **** Class I1 GBP IE00BYXWTN61 G1309T519 **BYXWTN6 BRAEI1G** 29416460 A14Y7R 10/6/2016 0.83 **** Class A USD IE0031574530 G1309T238 3157453 BRANEEA 1555585 260189 12/2/2003 1.69 **** Class A EUR IE0031574647 G1309T253 3157464 BRAEEEA 1555587 260191 17/7/2003 1.71 $\star \star \star \star$ Class A GBP IE0031574753 G1309T220 3157475 BRAEEAG 1555590 260192 27/9/2005 1.85 **** Class A1 USD IE00BYWTYS81 G1309T733 **BYWTYS8** BRNEA1U 37873322 A2DU24 7/7/2021 1.74 Class A1 EUR IE00BYXWTQ92 G1309T535 BYXWTQ9 BRAEA1E 29417347 A14Y7T 5/10/2015 1.71 **** Class A1 GBP IE00BYXWTR00 G1309T543 **BYXWTR0** BRAEA1G 29417352 A14Y7U Class B EUR A3CNL4 IE00BNKDZV56 G1309W132 Unknown RRAFRFII 111313539 24/5/2021 1 74 Class R EUR IE00BNKDZW63 G1309W124 Unknown BRAEREU 111313367 A3CNL5 10/5/2021 0.89

¹Based on the actual expenses over the trailing twelve month period ended 31/3/2024. ²Out of 287 Europe Large-Cap Value Equity funds as of 31/3/2024.

Class I Shares will generally be offered to institutional investors only, as determined by the fund's directors in their absolute discretion. The minimum initial subscription applicable to Class I Shares is \$1 million or its equivalent in another currency, save for Class I Shares with a GBP denominated currency for which there is a minimum initial subscription of £10,000.

Class A Shares may be offered by appointed distributors only. The minimum initial subscription applicable to A Shares is \$10,000 or its equivalent in another currency. A distribution fee of up to 1% of the net asset value of the relevant Class A Shares shall be payable out of the assets of the share class to the distributors.

Class I1 and A1 Shares are distributing share classes. Distributions are paid on an annual basis with the record date being the last business day of the calendar year.

This Fund promotes environmental and/or social characteristics and is classified as an Article 8 fund under the EU's Sustainable Finance Disclosure Regulation ("SFDR").

Additional Information for French investors: Investors should note that, relative to the expectations of the Autorité des Marchés Financiers, this UCITS presents disproportionate communication on the consideration of non-financial criteria in its investment policy.

Source: Brandes, MSCI. MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products. The MSCI Europe Index with net dividends captures large and mid cap representation of developed market countries in Europe. The MSCI Europe Value Index captures large and mid cap securities across developed Europe exhibiting value style characteristics, defined using book value to price, 12-month forward earnings to price, and dividend yield. The MSCI Europe Growth Index captures large and mid cap securities across developed Europe exhibiting growth style characteristics, defined using long-term forward earnings per share (EPS) growth rate, short-term forward EPS growth rate, current internal growth rate, long-term historical EPS growth trend, and long-term historical sales per share growth trend.

Diversification does not assure a profit or protect against a loss in a declining market.

Term definitions: https://www.brandes.com/termdefinitions

[©]2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed: and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. For more detailed information about the Morningstar Rating, including its methodology, please go to global.morningstar.com/managerdisclosures. For more detailed information about Morningstar's Analyst Rating, including its methodology, please go to global.morningstar.com/managerdisclosures/.

This document is an advertisement for marketing purposes. Before subscribing, please read the prospectus and the key information document for packaged retail and insurance-based investment products (the "PRIIPs KID") or, for UK investors, the key investor information document (the "UCITS KIID"). Shares in the Fund are offered only on the basis of information contained in the prospectus, PRIIPs KID, for UK investors the UCITS KIID, and the latest annual audited accounts. Copies are available free of charge from Brandes Investment Partners (Europe) Limited at Alexandra House, The Sweepstakes, Ballsbridge, Dublin, D04 C7H2, Ireland or on https://www.brandes.com/ucits/resources. The PRIIPs KID and UCITS KIID are available in English, Dutch, French, German and Spanish. The prospectus is available in English and German. For a summary of Shareholder Rights, go to https://www.brandes.com/docs/publication/handout/shareholderrightssummaryucits.

This report is produced by the manager for marketing purposes only and does not constitute an offer or solicitation to subscribe for shares in Brandes Investment Funds plc (the "Company"). For more information on the risks associated with the Fund, please refer to the section entitled Risk Factors in the main body of the prospectus and the Fund's supplement to the prospectus. Full details regarding the Fund are set out in the key information document for packaged retail and insurance-based investment products (the "PRIIPs KID") or, for UK investors, the key investor information document (the "UCITS KIID"), the prospectus, the articles of association and the latest financial reports published for the Company (collectively the "Fund Documents"). Before any subscription, it is recommended that you read carefully the Fund Documents. The information provided in this material should not be considered an investment advice within the meaning of the MiFID II Directive. Income may fluctuate in accordance with market conditions and taxation arrangements. Investment in the Fund described in this report carries a substantial degree of risk and places your capital at risk. The price and value of investments can go down as well as up. Your investment may be subject to a redemption fee. You may not get back the original amount invested and you may lose all of your investment. Strategies discussed are subject to change at any time by the manager in its discretion due to market conditions or opportunities. The foregoing reflects the thoughts and opinions of Brandes Investment Partners® exclusively and is subject to change without notice.

The Fund Documents may be obtained without cost by contacting the Administrator for the Fund, your Financial Representative, or at the offices of the paying agent or representative in each jurisdiction. Austria, Belgium, France, Germany, Luxembourg, Netherlands, and the United Kingdom: FE fundinfo (Luxembourg) S.à.r.I., 6 Boulevard des Lumières, Belvaux, 4369 Luxembourg. Spain: Allfunds Bank, S.A., Estafeta 6, la Moraleja, Complejo Plaza de la Fuente, Alcobendas, Madrid, Spain. Switzerland: Representative and Paying Agent: BNP Paribas Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, CH-8002 Zurich, Switzerland. Please note that not all share classes are available in each of the foregoing jurisdictions listed above. All official documentation is also available at www.brandes.com/ucits and you may obtain updated information on the net asset value of the relevant shares at www.fundinfo.com. This report may not be used in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. The fund is not offered or sold to "U.S. Persons" as defined in Regulation S of the U.S. Securities Act of 1933. This report is reserved for professional clients as defined by the European Directive 2004/39/EC dated 21 April 2004 (MiFID) and is not for retail distribution. Brandes Investment Partners (Europe) Limited is regulated by the Central Bank of Ireland and is registered in Ireland at the below address. Registration number 510203.

